Study #2020-0330
Effect of Pegloticase on reduction of Uric Acid in patients with Tumor Lysis Syndrome: A Pilot Pragmatic Clinical Trial
MD Anderson Study Status
Enrolling
Treatment Agent
Pegloticase, Rasburicase
Description
This trial studies the effect of pegloticase in reducing uric acid levels in patients with hyperuricemia (high blood levels of uric acid) caused by tumor lysis syndrome. Tumor lysis syndrome occurs when the breakdown products of cancer cells, such as uric acid, enter the blood stream. High levels of uric acid in blood may cause kidney damage and reduce kidney function. The goal of this trial is to learn if pegloticase may lower uric acid levels in blood when given to cancer patients with hyperuricemia caused by tumor lysis syndrome.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Tumor Lysis Syndrome
Study phase:
Phase IV
Physician name:
Sreedhar Mandayam
Department:
Emergency Medicine
For general questions about clinical trials:
1-866-967-2182
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.